Necitumumab

Necitumumab (Portrazza®), which received FDA approval on 24 November 2015, is used in disease spread to distant tissues, with squamous cell non-small cell lung cancer patients, together with gemcitabine and cisplatin as first-line treatment. Necitumumab has not been shown to provide benefit in patients with nonsquamous non-small cell lung cancer. Our drug exerts its effect on cancer cells through EGFR (epidermal growth factor receptor).
By inhibiting the functioning of the receptor called EGFR, it prevents cancer cell growth and new blood vessel formation. It also has the ability to kill cancer cells directly. Rash and reduced magnesium levels are its most frequently reported side effects.
Was this article helpful?
Your feedback helps us improve our content.



Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.